A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.
Timothy DevosTatjana GeukensAlexander SchauwvliegheKevin K AriënCyril BarbezangeMyriam CleerenVeerle CompernolleNicolas DaubyDaniël DesmechtDavid GrimaldiBart N LambrechtAnne LuytenPiet MaesMichel MoutschenMarta RomanoLucie SeylerMichel Toungouz NevessignskyKatleen VandenbergheJohan van GriensvenGeert VerbekeErika VliegheJean Cyr YombiLaurens LiesenborghsPeter VerhammeGeert MeyfroidtPublished in: Trials (2020)
ClinicalTrials.gov NCT04429854 . Registered on 12 June 2020 - Retrospectively registered.
Keyphrases
- phase ii
- open label
- clinical trial
- phase iii
- study protocol
- double blind
- end stage renal disease
- coronavirus disease
- phase ii study
- ejection fraction
- placebo controlled
- healthcare
- newly diagnosed
- sars cov
- palliative care
- randomized controlled trial
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- squamous cell carcinoma
- radiation therapy
- cross sectional
- rectal cancer
- respiratory syndrome coronavirus
- health insurance
- affordable care act